|
CN112028996A
|
|
Single domain antibodies targeting BCMA and uses thereof
|
|
CN112029001A
|
|
Chimeric antigen receptors targeting NK activating receptors
|
|
CN112063588A
|
|
Engineered immune cells and uses thereof
|
|
CN111849913A
|
|
Engineered immune cells and uses thereof
|
|
CN111849910A
|
|
Engineered immune cells and uses thereof
|
|
CN111729084A
|
|
Combination therapy of STING agonists with engineered immune cells
|
|
CN111218448A
|
|
Preparation and use of engineered immune cells
|
|
CN111269326A
|
|
Novel chimeric antigen receptor and use thereof
|
|
CN111234033A
|
|
Multi-chain chimeric antigen receptors and uses thereof
|
|
CN111235113A
|
|
Immune cells comprising chimeric antigen receptors and uses thereof
|
|
CN110964122A
|
|
T cell receptor fusion proteins and uses thereof
|
|
CN110885799A
|
|
Gene editing method based on adenovirus
|
|
CN112111013A
|
|
Universal chimeric antigen receptor T cell targeting claudin18.2, construction method and application thereof
|
|
CN109929845A
|
|
A kind of double sites sgRNA knock out the CRISPR/Cas9 system and application of RSPH6A gene
|
|
CN109913460A
|
|
A kind of double sites sgRNA knock out the CRISPR/Cas9 system and application of INS gene
|
|
CN109929846A
|
|
A kind of double sites sgRNA knock out the CRISPR/Cas9 system and application of LRRC20 gene
|
|
CN109971757A
|
|
A kind of double sites sgRNA knock out the CRISPR/Cas9 system and application of FOXR1 gene
|
|
WO2020103013A1
|
|
Modified t cells and uses thereof
|
|
CN111788307A
|
|
Engineered chimeric guide RNAs and uses thereof
|
|
CN107746831A
|
|
Universal CART/TCRT cells and its construction method with chemotherapeutic drug resistance
|
